Your browser is no longer supported. Please, upgrade your browser.
AUTL Autolus Therapeutics plc daily Stock Chart
Autolus Therapeutics plc
Index- P/E- EPS (ttm)-2.21 Insider Own- Shs Outstand38.79M Perf Week3.66%
Market Cap1.43B Forward P/E- EPS next Y- Insider Trans- Shs Float14.91M Perf Month17.76%
Income- PEG- EPS next Q- Inst Own22.62% Short Float3.32% Perf Quarter26.24%
Sales1.65M P/S864.29 EPS this Y- Inst Trans- Short Ratio10.57 Perf Half Y-
Book/sh7.30 P/B5.04 EPS next Y- ROA- Target Price37.50 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range19.17 - 53.24 Perf YTD47.20%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-27.21% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low102.11% ATR5.38
Employees82 Current Ratio- Sales Q/Q-25.40% Oper. Margin- RSI (14)57.37 Volatility13.26% 17.35%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.83 Prev Close36.80
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume46.92K Price38.75
Recom1.60 SMA2016.43% SMA5027.40% SMA20036.87% Volume27,881 Change5.30%
Oct-24-18Initiated H.C. Wainwright Buy $45
Nov-02-18 07:42AM  Autolus Therapeutics to Present New Data at the ASH Annual Meeting PR Newswire
Nov-01-18 09:10AM  Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 60th ASH Annual Meeting PR Newswire +10.53%
Oct-30-18 08:30AM  Autolus Therapeutics to Present at the Jefferies 2018 London Healthcare Conference PR Newswire
Oct-17-18 08:30AM  Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality PR Newswire
Sep-27-18 08:20PM  UK biotech raises bumper $2 billion, despite Brexit blues Reuters +7.12%
Aug-30-18 08:33AM  Autolus to Present at Upcoming Investor Conferences PR Newswire
Jun-22-18 08:13PM  [$$] Five Drug Startups Reveal Plans to Join Blitz of Biotech IPOs The Wall Street Journal
07:07PM  [$$] Autolus, ElectroCore IPOs Cap Strong Week for Life Sciences The Wall Street Journal
Jun-17-18 04:22PM  The IPO Outlook For The Week Of June 18: Pharma, Pharma And More Pharma Benzinga
Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.